Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q3 FY2020 Earnings Presentation
17 slides from Aurobindo Pharma's earnings presentation, Feb 6, 2020
Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
AUROBINDO February 6, 2020 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Sandra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI·400 051 25 th floor, Dalal Street, MUMBAI·400 001 Company Code No. AUROPHARM
Slide 2: Aurobindo Pharma Limited Q3FY20 Earnings Presentation
Aurobindo Pharma Limited Q3FY20 Earnings Presentation 6th February 2020
Slide 3: Disclaimer
Aurobindo Pharma Limited – Earnings Presentation 2 Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of
Slide 4: Index
Aurobindo Pharma Limited – Earnings Presentation 3 Index 1 Q3 Financial & Business Highlights 2 Financial Performance 3 Filings Snapshot
Slide 5: Q3FY20 Financial & Business Highlights
1 Q3FY20 Financial & Business Highlights 4
Slide 6: Consolidated Financial & Business Highlights – Q3FY20
Aurobindo Pharma Limited – Earnings Presentation 5 Consolidated Financial & Business Highlights – Q3FY20 In Rs Cr Revenue EBITDA Profit After Tax 5% QoQ 3% QoQ 10% QoQ 12% YoY 11% YoY 1% YoY 1,208 5,895 712 705 1,167 640 5,600 5,270 1,086 20.5% 20.8% 20.6% Q3FY19 Q2FY20 Q3FY20 Q3FY19 Q2FY20 Q3FY20 Q
Slide 7: Consolidated Financial & Business Highlights – Q3FY20
Aurobindo Pharma Limited – Earnings Presentation 6 Consolidated Financial & Business Highlights – Q3FY20 Revenue from operations at Rs. 5,895.0 crore, witnessed a strong growth of 11.9% YoY EBIDTA before Forex and Other income at Rs. 1,208.0 crore, an increase of 11.2% YoY; EBITDA margin is at 20.5%
Slide 8: Consistent Quarterly Performance
Aurobindo Pharma Limited – Earnings Presentation 7 Consistent Quarterly Performance Revenue ($ Mn) US Revenue ($ Mn) 831 404 418 783 797 387 733 753 339 353 630 635 679 318 271 282 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q3FY20 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q3FY20 EBITDA
Slide 9: US Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 8 US Business Performance Highlights In Rs Cr Revenue Revenue Mix 9MFY20 2,835 2,969 Injectables* Orals 2,433 18% 63% Total Injectables 25% Branded Oncology** 7% Dietary Supplements Q3FY19 Q2FY20 Q3FY20 OTC 10% 3% US Formulations • US revenue for Q3FY
Slide 10: EU, ARV, Growth Markets, API Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 9 EU, ARV, Growth Markets, API Business Performance Highlights In Rs Cr EU Revenues Growth Markets Revenues ARV Revenues API Revenues 341 346 313 922 1,476 806 1,401 319 281 790 238 1,293 Q3FY19 Q2FY20 Q3FY20 Q3FY19 Q2FY20 Q3FY20 Q3FY19 Q2FY20 Q3FY20
Slide 11: Financial Performance
2 Financial Performance 10
Slide 12: Consolidated Financial Performance
Aurobindo Pharma Limited – Earnings Presentation 11 Consolidated Financial Performance Rs Cr Q3FY20 Q3FY19 YoY Growth(%) Q2FY20 QoQ Growth(%) Revenue from operations 5,895.0 5,269.7 11.9 5,600.5 5.3 Gross Profit 3,330.0 2,879.8 15.6 3,232.2 3.0 Gross Margin 56.5% 54.6% 57.7% Overheads 2,122.0 1,793.
Slide 13: Debt Profile
Aurobindo Pharma Limited – Earnings Presentation 12 Debt Profile Fx Loan US$ Mn Debt as on (Rs Crore) Mar-18 Mar-19 Jun-19 Sep-19 Dec-19 Closing Rate1 US$ = INR 65.17 69.155 69.020 70.875 71.385 731 1,006 850 828 757 Fx Loan restated in INR 4,766.9 6,959.0 5,865.4 5,866.8 5,403.2 Rupee Loan 4.1 8.1
Slide 14: Filings Snapshot
3 Filings Snapshot 13
Slide 15: US Filings Snapshot as on 31st Dec 2019
Aurobindo Pharma Limited – Earnings Presentation 14 US Filings Snapshot as on 31st Dec 2019 Dermatology, Nasals and Opthalmic ANDA Filings Addressable Includes ANDAs of Orals, OTC, 391 Therapy ANDAs Market Size 318 73 (US$ Bn) CNS 98 24.8 Non - Injectables 49 Injectables CVS 86 25.9 154 132 ARV** 41
Slide 16: Global Filing details
Aurobindo Pharma Limited – Earnings Presentation 15 Global Filing details As at As at As at As at As at As at As at Category Approvals Mar 14 Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Dec 19 Formulations US* 336 376 398 429 478 541 572 418 (FA: 391, TA:27) 2,555 Dossiers (279 Europe** 1,542 1,756 2,224 2,5
Slide 17: Thank You
Thank You Investors Contact Investor Relations team ir@aurobindo.com 040-66725401